SHH inhibitors for the treatment of medulloblastoma

Area of Science:

• Pediatric oncology
• Molecular biology
• Cancer genetics

Background:

• Medulloblastoma is the most common pediatric malignant brain tumor.
• It is classified into four molecular variants: wingless, sonic hedgehog (SHH), Group III, and Group IV.
• The SHH molecular subgroup is defined by aberrant SHH signaling pathway activation, often due to mutations in PTCH1 or downstream genes.

Purpose of the Study:

• To provide an overview of SHH medulloblastoma.
• To discuss the current landscape of SHH inhibitors for treating SHH-driven medulloblastoma.
• To highlight the challenges associated with the clinical use of these inhibitors.

Main Methods:

• Review of existing literature on SHH medulloblastoma.
• Analysis of transcriptional profiling data for medulloblastoma stratification.
• Examination of preclinical (in vitro and in vivo) and clinical trial data for SHH inhibitors.

Main Results:

• SHH medulloblastoma is a distinct molecular subtype with specific genetic drivers.
• Numerous SHH inhibitors are in various stages of development, with some approved for other SHH-driven cancers.
• Preclinical studies demonstrate inhibitor efficacy, leading to ongoing Phase I and II clinical trials.

Conclusions:

• SHH inhibitors represent a promising therapeutic strategy for SHH medulloblastoma.
• Further research is needed to overcome challenges in their clinical application.
• Understanding SHH pathway dysregulation is crucial for developing effective pediatric brain tumor treatments.